Search
Andrew Bockis will discuss "What Lawyers Should Know About Hydrogen Hubs" at the Pennsylvania Bar Institute's Oil & Gas Law Conference 2023. This conference explores recent legislative and case law developments as well as technological advancements in the oil and gas industry. In addition to being a...
John Dixon moderated a panel on “New Challenges and Opportunities in Environmental Permitting” during the Pennsylvania Bar Institute’s 2023 Oil and Gas Law Conference. Also on the panel were attorneys from the Pennsylvania Department of Environmental Protection and Citizens for Pennsylvania’s Future...
Athira Sivan (Philadelphia) and Bill Warren (Harrisburg) presented on “The Non-Profit Legal Lifecycle: Legal Requirements for New CWOs From Formation to Operation” at the 2023 Pennsylvania Statewide Conference for Watershed Organizations on October 30, 2023. Their appearance before the group of...
Panel 4: The Connections Between Insurance and Litigation Funding Join Partner Brian Michalek and the University of Chicago Center on Law and Finance , in sponsorship with Burford Capital and Alliant, at the 2023 Chicago Conference on Litigation Finance. This conference will explore the policy...
This issue of Saul on ESG: Trends & Updates marks our first update tracking the legal trends and developments around environmental, social and governance (ESG). In recent years, we have been tracking and highlighting changes on the ESG front, but this regular publication will allow us to dive...
Saul Ewing’s Casey Grabenstein and Andrew Schwerin write that courts are divided on whether plaintiff bias justifies discovery about litigation funding. They argue litigation funding wouldn’t often create a conflict of interest for a plaintiff.
Contingent Liability Insurance Demystified Partner Brian Michalek will speak on a panel during the 2023 Transaction Solutions Symposium. More information to come.
On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...